The recent publication provides a strong theoretical basis to demonstrate that the dual inhibition of EZH2/EHMT2 methyltransferases can bring more effective prospects for cancer treatment (Soumyanarayanan and Dymock, 2016). The gene discussed is EZH2; the disease is cancer.